Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro

Surgery (United States)

Volumn 156, Issue 5, 2014, Pages 1167-1176

  Ferrari, Silvia Martina ^a   Fallahi, Poupak ^a   La Motta, Concettina ^a   Bocci, Guido ^a   Corrado, Alda ^a   Materazzi, Gabriele ^a   Galleri, David ^a   Piaggi, Simona ^a   Danesi, Romano ^a   Da Settimo, Federico ^a   Miccoli, Paolo ^a   Antonelli, Alessandro ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CLM 3; CLM 94; PROTEIN RET; PROTEIN TYROSINE KINASE INHIBITOR; PYRAZOLO[3,4 D]PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN A; 4-CHLORO-N-(1,1,3-TRIOXO-2,3-DIHYDROBENZO(D)ISOTHIAZOL-4-YL)BENZAMIDE; BENZAMIDE DERIVATIVE; CLM3 COMPOUND; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; SACCHARIN; VEGFA PROTEIN, HUMAN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG SCREENING; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLARY THYROID CANCER; PROTEIN EXPRESSION; THYROID CANCER; THYROID CANCER CELL LINE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; CARCINOMA, MEDULLARY; CELL CULTURE; CELL MOTION; CELL PROLIFERATION; CELL SURVIVAL; DRUG EFFECTS; THYROID NEOPLASMS;

APOPTOSIS; BENZAMIDES; CARCINOMA, MEDULLARY; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SACCHARIN; THYROID NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908282072     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2014.05.005     Document Type: Article

References (40)

1. M. Brassard, and G. Rondeau Role of vandetanib in the management of medullary thyroid cancer Biologics 6 2012 59 66
2. A. Taccaliti, F. Silvetti, G. Palmonella, and M. Boscaro Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers Curr Genomics 12 2011 618 625
3. B. González-Yebra, R. Peralta, A.L. González, M.A. Ayala-Garcia, M.E. de Zarate, and M. Salcedo Genetic alterations in a primary medullary thyroid carcinoma and its lymph node metastasis in a patient with 15 years follow-up Diagn Pathol 7 2012 63
4. A. Antonelli, P. Fallahi, S.M. Ferrari, C. Mancusi, M. Colaci, and L. Santarpia RET TKI: potential role in thyroid cancers Curr Oncol Rep 14 2012 97 104
5. C. Capp, S.M. Wajner, D.R. Siqueira, B.A. Brasil, L. Meurer, and A.L. Maia Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma Thyroid 20 2010 863 871
6. L. Mologni Development of RET kinase inhibitors for targeted cancer therapy Curr Med Chem 18 2011 162 175
7. H.A. Deshpande, S.N. Gettinger, and J.A. Sosa Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope Curr Opin Oncol 20 2008 19 24
8. Y.E. Nikiforov Thyroid carcinoma: molecular pathways and therapeutic targets Mod Pathol 21 2008 S37 S43
9. G. Tortora, F. Ciardiello, and G. Gasparini Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications Nat Clin Pract Oncol 5 2008 521 530
10. J. Klubo-Gwiezdzinska, K. Jensen, J. Costello, A. Patel, V. Hoperia, and A. Bauer Metformin inhibits growth and decreases resistance to anoikis in medullary thyroid cancer cells Endocr Relat Cancer 19 2012 447 456
11. C. Spinelli, A. Bertocchini, A. Antonelli, and P. Miccoli Surgical therapy of the thyroid papillary carcinoma in children: experience with 56 patients < or =16 years old J Pediatr Surg 39 2004 1500 1505
12. R.D. Blumenthal, and D.M. Goldenberg Methods and goals for the use of in vitro and in vivo chemosensitivity testing Mol Biotechnol 35 2007 185 197
13. A. Antonelli, S.M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, and L. Barani Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests Clin Endocrinol (Oxf) 69 2008 148 152
14. A. Antonelli, G. Bocci, C. La Motta, S.M. Ferrari, P. Fallahi, and A. Fioravanti Novel pyrazolopyrimidine derivatives as tyrosine kinase inhibitors with antitumoral activity in vitro and in vivo in papillary dedifferentiated thyroid cancer J Clin Endocrinol Metab 96 2011 E288 E296
15. A. Antonelli, G. Bocci, C. La Motta, S.M. Ferrari, P. Fallahi, and I. Ruffilli CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo J Clin Endocrinol Metab 97 2012 E528 E536
16. A. Antonelli, G. Bocci, P. Fallahi, C. La Motta, S. Martina Ferrari, and C. Mancusi CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo J Clin Endocrinol Metab 99 2014 E572 E581
17. S.S. Leong, R. Zeigel, T.M. Chu, S. Baylin, and E.A. Mirand A new cell line for study of human medullary thyroid carcinoma M. Andreoli, Advances in thyroid neoplasia 1981 Field Educational Italia Rome 95 108
18. F. Carlomagno, D. Salvatore, M. Santoro, V. de Franciscis, L. Quadro, and L. Panariello Point mutation of the RET proto-oncogene in the TT human medullary thyroid carcinoma cell line Biochem Biophys Res Commun 207 1995 1022 1028
19. S.C. Huang, J. Torres-Cruz, S.D. Pack, C.A. Koch, A.O. Vortmeyer, and P. Mannan Amplification and overexpression of mutant RET in multiple endocrine neoplasia type 2-associated medullary thyroid carcinoma J Clin Endocrinol Metab 88 2003 459 463
20. M.N. Nikiforova, and Y.E. Nikiforov Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis Expert Rev Mol Diagn 8 2008 83 95
21. K. Kaczirek, M. Schindl, A. Weinhäusel, C. Scheuba, C. Passler, and G. Prager Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines J Clin Endocrinol Metab 89 2004 2397 2401
22. A. Antonelli, S.M. Ferrari, P. Fallahi, S. Frascerra, S. Piaggi, and S. Gelmini Dysregulation of secretion of CXC alpha-chemokine CXCL10 in papillary thyroid cancer: modulation by peroxisome proliferator-activated receptor-gamma agonists Endocr Relat Cancer 16 2009 1299 1311
23. A. Antonelli, P. Fallahi, C. Nesti, C. Pupilli, P. Marchetti, and S. Takasawa Anti-CD38 autoimmunity in patients with chronic autoimmune thyroiditis or Graves' disease Clin Exp Immunol 126 2001 426 431
24. A. Antonelli, S.M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, and I. Marchetti Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration Eur J Endocrinol 159 2008 283 291
25. A. Antonelli, S.M. Ferrari, P. Fallahi, P. Berti, G. Materazzi, and M. Minuto Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells Clin Endocrinol (Oxf) 70 2009 946 953
26. F. Carlomagno, D. Vitagliano, T. Guida, M. Napolitano, G. Vecchio, and A. Fusco The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes Cancer Res 62 2002 1077 1082
27. F. Carlomagno, D. Vitagliano, T. Guida, F. Basolo, M.D. Castellone, and R.M. Melillo Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2) J Clin Endocrinol Metab 88 2003 1897 1902
28. M. Morisi, M. Celano, E. Tosi, S. Schenone, M. Navarra, and E. Ferretti Growth inhibition of medullary thyroid carcinoma cells by pyrazolo-pyrimidine derivatives J Endocrinol Invest 30 2007 RC31 RC34
29. J.H. Hanke, J.P. Gardner, R.L. Dow, P.S. Changelian, W.H. Brissette, and E.J. Weringer Discovery of a novel, potent, and Src family-selective tyrosine kinase inhibitor. Study of Lck- and FynT-dependent T cell activation J Biol Chem 271 1996 695 701
30. L. Wei, and S.V. Malhotra Recent development of cyclic amide (pyridone/lactam) moiety containing heterocycles as protein kinase inhibitors Curr Med Chem 17 2010 234 253
31. A. Antonsson, and J.L. Persson Induction of apoptosis by staurosporine involves the inhibition of expression of the major cell cycle proteins at the G(2)/m checkpoint accompanied by alterations in Erk and Akt kinase activities Anticancer Res 29 2009 2893 2898
32. I. Posadas, V. Vellecco, P. Santos, J. Prieto-Lloret, and V. Ceña Acetaminophen potentiates staurosporine-induced death in a human neuroblastoma cell line Br J Pharmacol 150 2007 577 585
33. L. Pedranzini, T. Dechow, M. Berishaj, R. Comenzo, P. Zhou, and J. Azare Pyridone 6, a pan-Janus-activated kinase inhibitor, induces growth inhibition of multiple myeloma cells Cancer Res 66 2006 9714 9721
34. R. van Amerongen, and A. Berns Targeted anticancer therapies: mouse models help uncover the mechanisms of tumor escape Cancer Cell 13 2008 5 7
35. Z.A. Knight, H. Lin, and K.M. Shokat Targeting the cancer kinome through polypharmacology Nat Rev Cancer 10 2010 130 137
36. J.M. Stommel, A.C. Kimmelman, H. Ying, R. Nabioullin, A.H. Ponugoti, and R. Wiedemeyer Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies Science 318 2007 287 290
37. C. Lanzi, G. Cassinelli, G. Cuccuru, N. Zaffaroni, R. Supino, and S. Vignati Inactivation of Ret/Ptc1 oncoprotein and inhibition of papillary thyroid carcinoma cell proliferation by indolinone RPI-1 Cell Mol Life Sci 60 2003 1449 1459
38. F. Carlomagno, D. Vitagliano, T. Guida, F. Ciardiello, G. Tortora, and G. Vecchio ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases Cancer Res 62 2002 7284 7290
39. H.H. Verbeek, M.M. Alves, J.W. de Groot, J. Osinga, J.T. Plukker, and T.P. Links The effects of four different tyrosine kinase inhibitors on medullary and papillary thyroid cancer cells J Clin Endocrinol Metab 96 2011 E991 E995
40. A. Antonelli, P. Fallahi, S.M. Ferrari, A. Carpi, P. Berti, and G. Materazzi Dedifferentiated thyroid cancer: a therapeutic challenge Biomed Pharmacother 62 2008 559 563